By applying whole exome sequencing and deep targeted sequencing on bladder 32 tumors, it was recently shown that tumors developed years apart in the same patients 33 share multiple mutations and hence are clonally related 1-3 . Furthermore, apparently 34 normal urothelium has been documented to contain mutations with low allele 35 frequencies (~3%) that are typically observed at high frequencies in tumors (clonal 36 mutations) 1-3 . Multiple studies have investigated genomic alterations in normal 37 appearing bladder tissue from cystectomy specimens, however using technologies 38 that do not allow detection of low-frequency mutations. The genomic alterations 39 observed in these studies include copy number alterations of chromosome 5, 9, 13, 40 16, and 17 as well as mutations or loss of RB1 and TP53 4-9 . These findings 41 corroborates the suggestions of the presence of field cancerization in the bladder. 42 Similar results have been reported in other tissue types, where studies have revealed 43 the presence of mutations in well-characterized cancer driver genes in apparently 44 healthy tissue and pre-cancer lesions 10-13 . 45 46 Bladder cancer (BC) is multifocal in almost half of the cases with primary tumour and 47 101 102 Analysis of field cancerization. Patients 1 and 2 presented with multifocal disease, 103 whereas patients 3 and 4 had unifocal disease. In patients 1 and 2, 39% (25/64) of the 104 mutations were N-Mutations, and 34% (22/64) were S-Mutations. Mutations called in 105 patients 3 and 4 were mainly T-Mutations, with only 5% (7/143) being N-Mutations and 106 13% (19/143) S-Mutations -indicating that uni-and multifocal patients may show 107 different levels of field cancerization. Mutations in known BC driver genes were 108 detected in both N-, S-and T-Mutation groups, most of them being among T-109 Mutations. However, in patient 1, two N-mutations were observed in bladder cancer 110 driver genes. Damaging mutations were present in all N-, S-and T-Mutation groups. 111 We detected the introduction of premature stop codons, mainly in the T-Mutation 112 group. However, for patient 1 premature stop codons were solely observed within the 113 N-and S-Mutations. Mutation allele frequencies (AFs) varied for the different 114 mutations detected but were generally low for N-Mutations and high for T-Mutations. 115 See Figure 1b and Table 1 for details. 116 117 131 132 Allele frequencies (median (min-max)) N-Mutations 0.042 (0.029-0.091) 0.067 (0.035-0.15) 0.070 (0.049-0.091) 0.059 (0.049-0.091) T-Mutations 0.23 (0.049-0.31) 0.13 (0.031-0.40) 0.17 (0.039-0.50) 0.16 (0.032-0.67) S-Mutations (Normal pool) 0.022 (0.0074-0.14) 0.033 (0.0064-0.063) 0.10 (0.014-0.13) 0.025 (0.0065-0.13) S-Mutations (Tumor pool) 0.20 (0.067-0.44) 0.077 (0.016-0.56) 0.13 (0.057-0.19) 0.15 (0.020-0.61)
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The multifocal and recurrent nature of bladder cancer has been explained by field 14 cancerization of the bladder urothelium. To shed light on field cancerization in the 15 bladder, we investigated the mutational landscape of normal appearing urothelium and 16 paired bladder tumors from four patients. Sequencing of 509 cancer driver genes 17 revealed the presence of 2-16 mutations exclusively localized in normal tissue 18 (average target read depth 634x). Furthermore, 6-13 mutations were shared between 19 tumor and normal samples and 8-75 mutations were exclusively detected in tumor 20 samples. More mutations were observed in normal samples from patients with 21 multifocal disease compared to patients with unifocal disease. Mutations in normal 22 samples had low allele frequencies compared to tumor mutations (p<2.2*10 -16 ). 23 Furthermore, significant differences in the type of nucleotide changes between tumor, 24 normal and shared mutations (p=2.7*10 -8 ) were observed, and mutations in APOBEC 25 context were observed primarily among tumor mutations (p=0.026). No differences in 26 functional impact between normal, shared and tumor mutations were observed 27 (p=0.23). Overall, these findings support the theory of multiple fields in the bladder, 28 Introduction in more than 50% of the patients with recurrent non-muscle invasive BC (NMIBC) 14 . 48 Moreover, recurrent BC is common as the majority of the patients with non-muscle 49 invasive BC (NMIBC) relapse within five years 15, 16 . Approximately 75% of patients with 50 BC present with NMIBC, and 5-25% of these will progress to muscle-invasive bladder 51 cancer (MIBC) 16, 17 . Multifocality and the frequent recurrences of BC are hypothesized 52 to originate from field cancerization of the bladder urothelium 18 . This concept was first 53 described in oral squamous epithelium in 1953 by Slaughter et al. as an explanation 54 of the high local recurrence rate of oral cancers 19 . More recent, field cancerization has 55 been described as an underlying mechanism for tumor development in various cancer 56 types, including BC 20 . 57 58 Field cancerization is understood as one or more areas, or fields, with mutated cells. 59 Normal cell lineages acquire mutations that are positively selected for in the 60 microenvironment of an otherwise healthy organ. Consequently, the mutant clone can 61 grow to produce fields of a monoclonal origin that predispose to malignant growth 62 within these transformed areas. The transformed cells may appear normal or 63 dysplastic 20,21 . Thomsen et al proposed a theory of multiple fields being present in the 64 4 bladder 2 where parallel expansion of different mutated stem cells might lead to multiple 65 transformed fields intermixed in the bladder urothelium. Tumors will mirror the genetic 66 alterations from the field from which it arose. This theory may explain the low 67 frequencies of mutations observed in normal samples 2 . 68 69 In our previous study of bladder cancer field cancerization we analyzed mutations in 70 adjacent normal tissue restricted to mutations observed in the tumor samples, and 71 consequently, non-tumor specific mutations were not investigated 2 . In this study, we 72 characterized mutations in normal appearing urothelium adjacent to tumors by deep 73 targeted sequencing. We detected high-impact mutations in known driver genes that 74 were not observed in the tumor. Furthermore, we observed mutations shared between 75 tumor and normal samples (tumor field effect) as well as mutations specific to the 76 tumors (mutations acquired later in development).
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Results
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We performed deep-targeted sequencing of DNA obtained from four patients (patients 80 1 to 4) with advanced bladder cancer, treated with radical cystectomy (see 81 Supplementary Fig. S2 and Supplementary Table S3 for detailed disease courses). 82 From each patient, DNA was procured from bulk tumor biopsies (n=2-7) and laser 83 microdissected (LMD) biopsies of normal appearing urothelium (n=6-11) (See 84 Supplementary Table S1 for overview of samples and sequencing information). 85 Individual bulk tumor samples were previously analyzed by whole exome sequencing 86 (WES) followed by deep targeted amplicon sequencing of LMD tumor and normal 87 samples guided by the original WES of bulk tumor 2 . In this present study, we expand 88 on our previous study to include the analysis of mutations uniquely present in normal 89 appearing adjacent tissue by deep targeted sequencing ( Figure 1a DNA as reference. We obtained an average target read depth of 634x (range: 360-96 1073). Following sequence read consolidation (UID error correction) 22 the average 97 target read depth was 69x (range: 36-129). In total, after filtering, we identified 30-93 98 5 mutations in the samples from the four patients. Of these, 2-16 were unique for pools 99 of normal samples (N-Mutations), 8-75 were unique for tumor pools (T-Mutations), and 100 6-13 were shared between tumor pools and normal pools (S-Mutations)( Figure 1b ). Interestingly, we observed N-Mutations in genes known to have a role in cancer 118 development. To corroborate our findings, we investigated the genes affected by non-119 synonymous mutations in 1889 patients with a total of 1934 samples from 11 different 120 BC studies using cBioPortal. In total, 0.6% to 23% (mean 4%) of the bladder tumors 121 harbored mutations in the same set of genes. The six most frequently non-122 synonymous mutated N-Mutation genes in the BC datasets were KMT2D (23%), 123 SPTA1 (8%), TRRAP (7%), PRKDC (6%), POLE (4%), and KDM5A (4%). Next, we assessed the proportion of APOBEC related mutagenesis. C>T/G mutations 162 in a TCW context, where W is either T or A, were evaluated as representing the 163 APOBEC signature 26 . We observed a significant difference between the proportion of 164 N-, S-, and T-Mutations in APOBEC related context (p=0.0011, Fisher's Exact Test). 165 In addition, we observed a significant difference when comparing C>T/C>G mutations 166 7 in an APOBEC-related context and C>T/C>G in non-APOBEC related context in N-, 167 S-, and T-Mutations (p=0.026, Fisher's Exact Test) ( Figure 3d ). 168 Finally, AFs for mutations in normal samples were significantly lower than for 169 mutations in tumor samples (p<2.2*10 -16 , Unpaired T-test)( Figure 3d ). There was no Here we characterized the field cancerization in four patients with advanced BC and 175 addressed the question of multiple mutated fields being present within the bladder. 176 Field cancerization was observed in all four patients analyzed, being more pronounced 177 in patients with multifocal disease compared to patients with unifocal disease. We 178 found that the normal appearing urothelium harbored private mutations not detected 179 in the tumor samples. We suggest that these mutations represent one or more fields 180 that have not lead to tumor development. Additionally, we detected mutations that 181 were shared between normal and tumor samples, representing mutations from the 182 field developing into a tumor. Mutations unique for tumor samples were also present, 183 indicating further genomic evolution of the tumor after initial development from the 184 field. 185 186 Different origins of these mutated cells have been proposed 21 . These include 187 intraepithelial migration and/or luminal seeding of carcinoma cells from existing tumors 188 followed by implantation of the carcinoma cells -eventually giving rise to recurrent 189 tumors. Another theory is that the field develops before the tumor from an altered stem 190 cell embedded in the urothelium. Following this, the altered clone can expand, leading 191 to a population of mutated daughter cells forming a cancerized field 20,21 . 192 193 Our analysis showed that mutations were present at low frequencies in the normal We observed that the expected impact of N-, S-and T-Mutations was the same across 221 all three groups. We would expect S-Mutations and T-Mutations to have a higher 222 impact than N-Mutations, as these two groups drive initial tumor formation and later 223 tumor evolution. In the Martincorena et al studies, high impact mutations, missense 224 mutations, and cancer driver mutations were observed in normal tissue from non-225 cancerous individuals 11, 13 . Consequently, these findings may imply that tumor 226 formation is more dependent on the affected genes, combination of genes, and the 227 order in which mutations occur 30 . Additionally, from our analysis it is not possible to In addition, we observed that mutations in APOBEC context were mainly present in 232 the T-Mutation group. This is in concordance with other studies that have suggested 233 that APOBEC mediated mutagenesis is a late event in tumor evolution 31,32 . 234 9 Furthermore, most of the non-APOBEC related C>T mutations observed in the normal 235 samples were found in a CpG context (7/11) and may hence be related to the age 236 related signature 1, in accordance with the fact that mutations accumulate in normal 237 cells over time 24 . 238 239 We hypothesize that field cancerization may have prognostic and predictive value. 240 However, as stated previously, results from our and other studies have shown that 241 mutations do indeed occur in normal cells without leading to cancer development. This Supplementary Fig. S1 ). To ensure normal 296 sample specificity, initial N-Mutations were evaluated in previously generated WES 297 data. Mutations were discarded if present with two or more alternate reads in any of 298 the corresponding tumor samples. 299 Any positions with more than two alleles were excluded and all remaining mutations 300 were reviewed manually using the Integrative Genomics Viewer (IGV) 35 No. N-Mutations 16 (53%) 9 (26%) 2 (4%) 5 (5%) SOX2  NTRK3  EGFR  FOS  EPHA3  NUP214  CDH1*  APC2  DOT1L  TSPAN31  PLCG1  NF1  CUL3  BCL2L2  PAK5  ERCC3  MYCL  ADGRB3  MUC1  TCF3  TET2  WT1  FANCA  CDH1  TBX3 GRM3  TPO  PIK3C2B  IDH2  NTRK3  RAD51B  JAK3  CDKN1A*  RAD51B  IGF1R  NF2  SF3B1  GRIN2A  SPEN  PTPRF  FOXO3  BCL3  IGFBP3  RET  CDK6  RPTOR  MAPK3  KEL  EGF  KAT6B  CDK2  NOS3  PRKDC  NSD1  FANCF  PLCG2   KDM5A  EP300*  INPP4B  ZNF703  RUNX1T1  CBFA2T3  PPP2R1A  MST1R  IRF2  JUN  ADCY9  PPP2R2B  NSD1   EGFR  NCOA2  POLE  DNMT1  KDM5C   Patient 4   IGF1R  CDKN2B  FLT1  NTRK3  GRIN2A  COL1A1  SOX9  TBX3*  THBS1  MSH2  BRCA2  MAP3K1*  SMAD3  PTCH1  POLE  NUP214  SUFU  FLT1  GRIN2A  DDR2  ABL1  ROS1  ASXL1  CREBBP  FBXW7*  CBL  CBFA2T3  LAMA1  DGKB  EPHA8  EPHA5  EPHA8  LOC101928120  RPS6KB1  ZNF331  APC2 TRRAP  KAT6A  PRKDC  EPHB4  CCND2  TCF12  PML  BCOR  BCORL1  BCR  CDC25A  FANCD2  FES  BCORL1  SPTA1  TBX3  CDX2  FGFR3  EP300  BAP1  EPHA2  SMAD2  PAFAH1B2  BAP1  KMT2D  MYH9  FANCD2  ERBB2  TP53 MCL1  LZTR1  EPHB6  KDM5A  EXT2  CD79B  PLCG2  KMT2D  EPHB2  PIK3CA  MCL1  IRS2  GATA2  ABL2  GATA6  KAT6A  PPARA  KALRN  MPL  KALRN  CDKN1A  CHEK2  APC  PRKCA  CBFB  MAGI2  HDAC2  FLNC  JUN  NBN  EP400  CARD11  PLCG1  CCND1 Targ. seq. WES 
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